Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

PARTIAL CONVERSIONS OF CONVERTIBLE LOAN

Reference is made to the announcement (the "**Announcement**") and circular (the "**Circular**") of MicroPort Scientific Corporation (the "**Company**") dated 5 April 2024 and 6 May 2024 in relation to the Convertible Facility Agreement and the transaction contemplated thereunder. Capitalised terms used herein shall have the same meanings as defined in the Announcement and the Circular unless the context requires otherwise.

The Company recently received certain conversion notices from the Lenders to exercise the conversion rights attaching to the Convertible Loans to convert part of the loans in the total principal amount of US$41,500,000 (equivalent to HK$324,882,750) into 43,549,965 Conversion Shares at the conversion price of HK$7.46 per Conversion Share.

Accordingly, on 4 August 2025, 43,549,965 Conversion Shares, representing approximately 2.34% of the total number of issued Shares immediately before the issue of the Conversion Shares and approximately 2.29% of the total number of issued Shares as enlarged by the issue of the Conversion Shares, were allotted to the relevant Lenders in accordance with the terms and conditions of the Convertible Loan.

The Conversion Shares shall rank pari passu with, and carry the same rights in all aspects (including the rights to dividends) as, the other Shares in issue as at the date of the allotment and among themselves in all respects.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the People's Republic of China, 4 August 2025

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida and Ms. Weiqin Sun; and the independent nonexecutive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *for identification purpose only*